Company Overview

In March 2018, IQ-AI™ Ltd acquired Imaging Biometrics, LLC, a Wisconsin USA-based healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics supplies medical technology solutions and has a strong neuroimaging product portfolio. This is the second acquisition made by IQ-AI in the medical imaging space after acquiring Stone Checker Software Ltd in 2017.

Please find more information on the Imaging Biometrics website www.imagingbiometrics.com and the StoneChecker website www.stonechecker.com.

News & Announcements Highlights

VIEW ALL -

Shareholder Information

IQ-AI Ltd ordinary shares are traded on the Standard List of the London Stock Exchange. The IQ-AI Ltd ticker code is IQAI
There are no restrictions on the transfer of shares.

Investor Relations

IQ-AI Directors

Trevor Brown

Trevor Brown is the Chief Executive Director of IQ-AI Ltd. Most recently a director of Feedback plc, MRS plc, and Remote Monitored Systems plc, Trevor is currently a director of Braveheart Investment Group plc.

DR. AL MUSELLA

Dr. Musella, a retired podiatrist and technologist, is founder and president of The Musella Foundation For Brain Tumor Research & Information, Inc, a 501(c)(3) nonprofit public charity established in 1997 to help brain tumor patients through emotional and financial support, education, advocacy and fundraising for brain tumor research.

In this role, Dr. Musella established the first clinical trial database for brain tumors, upon which the National Cancer Institute modeled Clinicaltrials.gov. Dr. Musella has issued more than $19.3 million in brain tumor research grants and co-payment assistance grants to help patients access needed treatments. He also advocated for FDA and Medicare approval for Optune, Temodar, Gliadel, Gleolan, Avastin and many other treatments. His current efforts include lobbying for the “Promising Pathway Act,” legislation that accelerates the clinical trial approval process in order to move new drugs to market more efficiently.

Brett Skelly

Brett has been working in the financial sector for GBAC Limited for over 16 years carrying out various roles including preparing accounts and auditing a wide range of large and SME companies as well as preparing management information and forecasts. He has been involved in developing business plans and also been involved in a number of company sales and MBOs over the years.

In December 2017, Brett became the outsourced financial controller of Braveheart Investment Group Plc and is also the outsourced financial controller at Anticus Partners Limited.

Michael Schmainda

Michael has a 20-year history of successfully building global medical imaging businesses including Prism Clinical Imaging and Imaging Biometrics. As co-founder of IB, he has overseen all aspects of the company's development, operation, and growth since its inception. He has established strong collaborative relationships with leaders in the medical imaging field who drive new product development and has led the translation and commercialisation of sophisticated imaging solutions, achieved regulatory approvals in the US and Europe, and global product adoption.

Michael's career began with 3M Company, a company renowned for bringing new products to market, where he held leadership roles across multiple industries including the life science sector. Prior to IB, Michael was a foundational member of Prism Clinical Imaging, secured the initial investment for the company, and served as president and COO.

Company Advisors

  • Peterhouse Capital Limited
  • New Liverpool House, 15 Eldon Street, London EC2M 7LD
  • PKF Littlejohn LLP
  • 15 Westferry Circus, London E14 4HD
  • Barclays Bank plc
  • 39 / 41 Broad Street, St Helier, Jersey JE4 8PU
  • Share Registrars Ltd
  • Suite E, First Floor, 9 Lion & Lamb Yard, Farnham, Surrey GU9 7LL

Significant Shareholders

As at 1 March 2024, as far as the Directors are aware, the following shareholders
are interested in 3% or more of the issued share capital of the Company.

Total shares in issue: 221,709,789 Ordinary Shares of £0.01 each

Contact Us

iq-ai@imagingbiometrics.com

IQ-AI Ltd
IFC 5
St Helier, Jersey, Channel Islands
JE1 1ST

IQ-AI Ltd is a Jersey Registered Public Company #2044

 

TOP